Pre-earnings brief
Reports
Thu, Nov 5, 2026
Est. EPS
—
Est. revenue
—
Implied move
±10.0%
EPS beat rate
63%
Est. EPS
$1.98
Est. Rev
$113.6B
Impl. Move
±4.0%
Protagonist Therapeutics, Inc. (PTGX) is a biotechnology company focused on developing novel therapies for serious diseases. With a market cap of $9 billion, it operates in the health care sector, which is increasingly important as the demand for innovative treatments continues to grow.
Last quarter
In Q2 2026, Protagonist reported an EPS of $2.29, beating estimates by 8.53%. The stock reacted positively, gaining 1.11% the following day.
Management promises and guidance
EPS beat streak
2Q
EPS beat rate
63%
Avg EPS surprise
+398.56%
Avg 1-day reaction
-0.20%
Overall, expectations are mixed as the company has shown both strong earnings surprises and disappointing revenue figures in the past.
Bull case
If Protagonist continues its trend of beating EPS estimates, it could signal strong operational efficiency and growth potential, attracting more investor interest.
Bear case
Conversely, any signs of revenue stagnation or increased R&D costs without corresponding results could lead to a negative market reaction.
Key metrics to watch
Earnings Per Share (EPS)
$2.11EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
N/AWhile specific revenue estimates are not available, growth in revenue is critical for assessing the company's market performance.
The print will turn on these.
Q1
What will the EPS be for Q3 2026, and how does it compare to the previous quarter?
A strong EPS could reinforce investor confidence, while a miss might raise concerns about the company's growth trajectory.
Q2
What updates will management provide on R&D spending and its impact on future revenue?
Investors will want clarity on how R&D investments are translating into potential revenue streams, which is crucial for a biotech firm.
Why consensus could be wrong
The market may be underestimating the potential for Protagonist's pipeline to deliver significant revenue growth, particularly if recent clinical trials yield positive results.
Supporting evidence
The company has a history of beating EPS estimates, suggesting operational strength.
Options pricing indicates a higher expected move than historical averages, reflecting investor uncertainty.
Strong R&D commitments could lead to breakthroughs that the market is not currently pricing in.
Key risk
If the company reports an EPS significantly above $2.30, it could challenge the current cautious sentiment.
Pre-commit to what would confirm each case.
The market is weighing the company's ability to sustain growth against its investment in R&D and potential revenue generation.
Bull confirmed if
An EPS of $2.30 or higher would confirm strong operational performance and growth potential.
Bear confirmed if
An EPS below $2.00 would raise concerns about profitability and future growth.
What the market is pricing for the move.
Implied Move
±10.11%
Historical Avg
±1.3%
The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings announcement.
Options are pricing ±10.0% while PTGX has averaged ±1.3% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
26.8%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 12 of 30 (40%)
This setup has occurred 30 times across Health Care in the last 2 years. 12 of 30 faded and 18 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.4%, with a raw directional average of -0.4% (modestly negative historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$8.3M
58,629 sh
1 insider
Net
$8.3M
Net selling
Most Active Insiders· 2 open-market trades
$8.3M
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
119.66%
of float
Insider
0.71%
of float
Holders
486
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
10,307,837 sh · $1.5B
15.93%
5.4%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Protagonist beats EPS expectations, history suggests a potential stock increase of around 0.68% on average the following day, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance from management.
Miss
A miss on EPS could lead to a decline of approximately 0.73% on average, indicating investor disappointment.
The lines on the call that would change the story.
R&D Spending
As a biotech firm, investment in research and development is crucial for future product pipeline and innovation.
Recent Transactions
Sep 30, 2026 · @ $141.78
46,034 sh
$6.5M
Sep 30, 2026 · @ $141.77
12,595 sh
$1.8M
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Farallon Capital Management LLC
6,348,906 sh · $894.7M
9.81%
Flat
RTW Investments LP
5,061,175 sh · $713.2M
7.82%
0.0%
Vanguard Portfolio Management LLC
3,629,298 sh · $511.4M
5.61%
4.3%
Wellington Management Group, LLP
3,416,781 sh · $481.5M
5.28%
-5.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.